The Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

Our data shows VIZZ (aceclidine 1.44%) received FDA approval in July 2025, positioning the once-daily, preservative-free ...

The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...

The US Food and Drug Administration (FDA) approved San Diego, USA-based LENZ Therapeutics’ VIZZ (aceclidine ophthalmic ...